Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Integra LifeSciences Expects FY24 Revenue of $1.672B-$1.687B (Prior $1.603B-$1.618B) Vs $1.616B Est, Adj EPS of $3.01-$3.11 (Prior $3.15-$3.25) Vs $3.19 Est

Author: Benzinga Newsdesk | May 06, 2024 06:08am

2024 Outlook

For the full year 2024, the Company is updating its revenue and adjusted EPS expectations to $1.672 to $1.687 billion and $3.01 to $3.11, respectively. The revenue range represents reported growth of 8.4% to 9.4%, with organic growth of 3.3% to 4.3%, reflecting the completion of the Acclarent acquisition and the removal of approximately $10 million of revenue from the relaunch of SurgiMend and PriMatrix beginning in the second half.

Posted In: IART

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)

07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)

07/01/2024 Equinix, Inc. (EQIX)

07/02/2024 Intel Corporation (INTC)

07/05/2024 AXT, Inc. (AXTI)

07/05/2024 Altimmune, Inc. (ALT)

07/09/2024 Li Auto Inc. (LI)

07/12/2024 Inari Medical, Inc. (NARI)

07/12/2024 Sprout Social, Inc. (SPT)

07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)